06Mar/19

New Drug for Episodic Cluster Headache! Lilly Receives FDA Priority Review Designation for A Novel CGRP Antibody Emgality for the Preventive Treatment

Pharmaceutical giant and Company Eli Lilly Recently announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality (galcanezumab-gnlm) injection forRead More…